These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37410085)

  • 1. Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study.
    Veeken LD; Opdam MAA; Verhoef LM; Popa C; van Crevel R; den Broeder AA
    Rheumatology (Oxford); 2024 May; 63(5):1246-1250. PubMed ID: 37410085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.
    den Broeder AA; Verhoef LM; Fransen J; Thurlings R; van den Bemt BJF; Teerenstra S; Boers N; den Broeder N; van den Hoogen FHJ
    Trials; 2017 Aug; 18(1):403. PubMed ID: 28854956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.
    Henry J; Gottenberg JE; Rouanet S; Pavy S; Sellam J; Tubach F; Belkhir R; Mariette X; Seror R;
    Rheumatology (Oxford); 2018 Mar; 57(3):538-547. PubMed ID: 29267905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis.
    Md Yusof MY; Iqbal K; Darby M; Lettieri G; Vital EM; Beirne P; Dass S; Emery P; Kelly C
    Rheumatology (Oxford); 2020 Oct; 59(10):2838-2846. PubMed ID: 32065634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
    Wade SD; Kyttaris VC
    Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells.
    Opdam MAA; de Leijer JH; den Broeder N; Thurlings RM; van der Weele W; Nurmohamed MT; Kok MR; van Bon L; Ten Cate DF; Verhoef LM; den Broeder AA
    Rheumatology (Oxford); 2022 Dec; 62(1):330-334. PubMed ID: 35686851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience.
    Evangelatos G; Fragoulis GE; Klavdianou K; Moschopoulou M; Vassilopoulos D; Iliopoulos A
    Rheumatology (Oxford); 2021 May; 60(5):2375-2382. PubMed ID: 33175958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
    Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
    J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
    Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
    Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
    Grøn KL; Glintborg B; Nørgaard M; Mehnert F; Østergaard M; Dreyer L; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2020 Aug; 59(8):1949-1956. PubMed ID: 31764977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.
    McClure ME; Zhu Y; Smith RM; Gopaluni S; Tieu J; Pope T; Kristensen KE; Jayne DRW; Barrett J; Jones RB
    Rheumatology (Oxford); 2021 Mar; 60(3):1491-1501. PubMed ID: 33141217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis.
    Shi Y; Wu Y; Ren Y; Jiang Y; Chen Y
    Int J Rheum Dis; 2019 Aug; 22(8):1361-1370. PubMed ID: 31099191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of rituximab in resistant palindromic rheumatism: first report in literature.
    Raghavan P; Sreenath S; Cherian S; Shenoy PD
    Clin Rheumatol; 2019 Sep; 38(9):2399-2402. PubMed ID: 31076945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: A single-center experience in Taiwan.
    Wang KC; Liao HT; Chen WS; Lai CC; Chou CT; Chen MH; Tsai CY
    Int J Rheum Dis; 2019 May; 22(5):860-868. PubMed ID: 30761753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study.
    Dumusc A; Alromaih F; Perreau M; Hügle T; Zufferey P; Dan D
    Arthritis Res Ther; 2023 Jun; 25(1):91. PubMed ID: 37264414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.
    Md Yusof MY; Kabia A; Darby M; Lettieri G; Beirne P; Vital EM; Dass S; Emery P
    Rheumatology (Oxford); 2017 Aug; 56(8):1348-1357. PubMed ID: 28444364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
    Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
    Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
    Tony HP; Krüger K; Cohen SB; Schulze-Koops H; Kivitz AJ; Jeka S; Vereckei E; Cen L; Kring L; Kollins D
    Arthritis Care Res (Hoboken); 2019 Jan; 71(1):88-94. PubMed ID: 30295429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study.
    Vassilopoulos D; Delicha EM; Settas L; Andrianakos A; Aslanidis S; Boura P; Katsounaros M; Athanassiou P; Tempos K; Skarantavos G; Antoniadis C; Papazoglou S; Sakkas L; Galanopoulou V; Skopouli F; Boki K; Daoussis D; Vritzali E; Sfikakis PP
    Clin Exp Rheumatol; 2016; 34(5):893-900. PubMed ID: 27383049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.